Vitura Health Past Earnings Performance
Past criteria checks 2/6
Vitura Health has been growing earnings at an average annual rate of 58.2%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 58.1% per year. Vitura Health's return on equity is 8.5%, and it has net margins of 2.8%.
Key information
58.2%
Earnings growth rate
96.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 58.1% |
| Return on equity | 8.5% |
| Net Margin | 2.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise
Oct 17
Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Oct 13Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture
Sep 07Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings
Aug 12Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Aug 12The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Feb 25Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)
Dec 13Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet
Nov 21Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?
Nov 01Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Jul 18Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%
Sep 12If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity
Sep 05Revenue & Expenses Breakdown
How Vitura Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 124 | 4 | 29 | 0 |
| 31 Mar 24 | 122 | 6 | 27 | 0 |
| 31 Dec 23 | 120 | 9 | 25 | 0 |
| 30 Sep 23 | 119 | 12 | 23 | 0 |
| 30 Jun 23 | 117 | 14 | 20 | 0 |
| 31 Mar 23 | 107 | 12 | 19 | 0 |
| 31 Dec 22 | 97 | 10 | 19 | 0 |
| 30 Sep 22 | 82 | 8 | 17 | 0 |
| 30 Jun 22 | 67 | 6 | 16 | 0 |
| 31 Mar 22 | 54 | 5 | 12 | 0 |
| 31 Dec 21 | 42 | 5 | 8 | 0 |
| 30 Sep 21 | 32 | 3 | 6 | 0 |
| 30 Jun 21 | 22 | 1 | 5 | 0 |
| 31 Mar 21 | 15 | 0 | 5 | 0 |
| 31 Dec 20 | 7 | -2 | 5 | 0 |
| 30 Sep 20 | 4 | -3 | 5 | 0 |
| 30 Jun 20 | 0 | -4 | 4 | 0 |
| 31 Mar 20 | 0 | -4 | 4 | 0 |
| 31 Dec 19 | 0 | -4 | 3 | 0 |
| 30 Sep 19 | 0 | -3 | 3 | 0 |
| 30 Jun 19 | 0 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
Quality Earnings: VIT has high quality earnings.
Growing Profit Margin: VIT's current net profit margins (2.8%) are lower than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIT has become profitable over the past 5 years, growing earnings by 58.2% per year.
Accelerating Growth: VIT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VIT had negative earnings growth (-74.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (26.6%).
Return on Equity
High ROE: VIT's Return on Equity (8.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vitura Health Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |